Quest Diagnostics (DGX)
NYSE:DGX
Want to see DGX full AI Analyst Report?
DGX Stock Chart & Stats
$191.42
-$0.03(-0.02%)
At close: 4:00 PM EST
$191.42
-$0.03(-0.02%)
Day’s Range― - ―
52-Week Range$160.02 - $213.50
Previous CloseN/A
Volume143.08K
Average Volume (3M)794.25K
Market Cap
$21.03B
Enterprise Value$27.69B
Total Cash (Recent Filing)$420.00M
Total Debt (Recent Filing)$6.92B
Price to Earnings (P/E)19.4
Beta0.15
Next Earnings
Apr 21, 2026EPS Estimate
2.37Next Dividend Ex-DateN/A
Dividend Yield1.8%
Share Statistics
EPS (TTM)2.42
Shares Outstanding109,866,320
10 Day Avg. Volume684,038
30 Day Avg. Volume794,246
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)2.69
Price to Sales (P/S)1.75
P/FCF Ratio14.17
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit7.55
Enterprise Value/Ebitda13.63
Forecast
1Y Price Target
$220.00Price Target Upside14.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)10.63
Revenue Forecast (FY)$11.76B
Bulls Say, Bears Say
Bulls Say
Guidance And DemandAnalyst highlights guidance that exceeds expectations, indicating stronger demand for diagnostic services and potential upside to revenue forecasts.
Organic Volume GrowthAnalyst points to sustained organic test-volume growth driven by patient testing and market share gains, supporting higher-than-expected top-line momentum.
Partnerships And Test InnovationAnalyst emphasizes expanding co‑lab partnerships, consumer-testing channels, and new diagnostic launches that broaden the addressable market and could support margin improvement.
Bears Say
Payer And Reimbursement UncertaintyAnalyst highlights payer coverage uncertainty for the Haystack colorectal cancer test, noting a Medicare Advantage assessment is pending and commercial payer negotiations remain inconsistent, which could limit realization of billed revenues.
Transformation CostsAnalyst cautions that ongoing large-scale transformation investments are weighing on near‑term profitability and may limit margin recovery.
Weather And Insurance Exchange PressureAnalyst warns that severe weather disruptions and pressures from insurance exchange dynamics are creating a revenue headwind that could constrain sales in impacted regions.
Quest Diagnostics News
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was $160.02 and its highest was $213.50 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $21.03B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Apr 21, 2026 which is in 4 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Feb 10, 2026. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.363 by $0.057.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.8 which represents an annual dividend yield of 1.8%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.37.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 109,866,320 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $2.42 in its last earnings report, beating expectations of $2.363. Following the earnings report the stock price went up 7.373%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in DGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$220.00 (14.93% Upside)
$220.00 (14.93% Upside)
Blogger Sentiment
Bullish
DGX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $538.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.52%
12-Months-Change
Fundamentals
Return on Equity
13.88%
Trailing 12-Months
Asset Growth
0.45%
Trailing 12-Months
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
DGX Company Deck
DGX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong organic growth, meaningful volume expansion, double-digit full-year revenue and EPS growth, a sizable increase in cash from operations, robust consumer and advanced diagnostics momentum, and clear cost-saving/automation progress. Near-term challenges include margin dilution from new low-margin CoLab ramping and implementation costs, a small decline in revenue-per-requisition driven by large-volume lower-price relationships, weather-related seasonality risk in early 2026, cash-flow comparatives due to one-time items, and unresolved structural/regulatory PAMA risks and some reimbursement uncertainties for new oncology tests. On balance the company presented positive operating and financial momentum with manageable near-term headwinds.View all DGX earnings summariesDGX Revenue Breakdown
97.73% Diagnostic Information Services
2.27% DS businesses
DGX Stock 12 Month Forecast
Average Price Target
$220.00
▲(14.93% Upside)
Technical Analysis
Ownership Overview
0.46% Insiders
30.80% Mutual Funds
0.71% Other Institutional Investors
39.74% Public Companies and
Individual Investors